EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Xpert MTB/XDR performance in non-sputum samples for diagnosis of drug-resistant tuberculosis at a North Indian tertiary care center

Binit Kumar Singh iD, Pankaj Jorwal iD, Nishant Thakur, Manish Soneja, Naveet Wig, Ankita Anand, Shikha Dhawan

Journal of Clinical Microbiology · 08.07.2026 · 64 (7)

DOI: 10.1128/jcm.01401-25 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 08.07.2026. Verfasst von Binit Kumar Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Molecular Diagnostic Techniques, Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid diagnosis of drug-resistant tuberculosis (DR-TB) is very challenging, specifically in extra-pulmonary TB specimens. The current study was performed on non-sputum specimens. All specimens were subjected on Xpert MTB/RIF Ultra followed by Xpert MTB/XDR, Ziehl-Neelsen (ZN) Staining, liquid culture, line probe assay (LPA), and drug susceptibility testing (DST). Out of 1,152 non-sputum specimens, 218 were observed to be positive on Xpert MTB/RIF Ultra and were selected for further investigation. From 218 MTBC positive, Xpert MTB/XDR yielded 174 (79.8%) positive while 25 (11.5%) were negative. On comparison with reference standards, ZN smear, and culture, the sensitivity was 100% and 95.51% with specificity of 17.86% and 18.63%, respectively. DST sensitivity and specificity were 84.62% and 96.61%, 83.33% and 96.88%, 50% and 98.75%, 50% and 98.72%, and 50% and 98.75%, respectively, for isoniazid, fluoroquinolones, amikacin, kanamycin, and capreomycin in culture positive specimens. The sensitivity and specificity of Xpert MTB/XDR assay, compared with LPA (MTBDR plus and MTBDR sl ), was between 94.12%–100% and 98.39%–100%, respectively. Sensitivity and specificity of Xpert MTB/XDR matched with culture-DST and LPA results for all the tested drugs. Its placement in diagnostic algorithms with Xpert MTB/RIF Ultra under National TB Programs will enhance patient outcome by providing prompt switch to a DST guided treatment regimen. IMPORTANCE This study provides crucial evidence supporting the use of Xpert MTB/XDR for rapid detection of DR-TB in non-sputum specimens including extra-pulmonary specimens, where diagnosis remains challenging due to paucibacillary in nature. By demonstrating high sensitivity and specificity compared with culture-DST and LPA, the assay shows strong potential to be integrated into the National TB Elimination Program (NTEP) diagnostic algorithm. Early detection of resistance to isoniazid, fluoroquinolones, and second-line injectables enables timely transition to DST-guided treatment, reducing delays and improving patient outcomes. The findings highlight the assay’s ability to reduce dependency on conventional laboratory-based DST, shortening turnaround time and strengthening decentralized diagnostic capacity. This study provides programmatic evidence for policy-level adoption, supporting India’s efforts toward DR-TB control and elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisMolecular Diagnostic TechniquesTuberculosis, Multidrug-ResistantExtensively Drug-Resistant TuberculosisHumansSensitivity and SpecificityIndiaTertiary Care CentersMicrobial Sensitivity TestsAntitubercular AgentsRapid Diagnostic TestsBacteriological Techniques

Stichwörter der Autor:innen

Xpert MTB/ RIF ultraXpert MTB/XDR assayline probe assayliquid culture & DST

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Centre for Social Integration and Borderless World, Uttar Pradesh, India.

ORCID-Profile: Binit Kumar Singh, Pankaj Jorwal

Zitieren

APA

Singh, B. K., Jorwal, P., Thakur, N., Soneja, M., Wig, N., Anand, A., & Dhawan, S. (2026). Xpert MTB/XDR performance in non-sputum samples for diagnosis of drug-resistant tuberculosis at a North Indian tertiary care center. Journal of Clinical Microbiology, 64(7). https://doi.org/10.1128/jcm.01401-25

Vancouver

Singh BK, Jorwal P, Thakur N, Soneja M, Wig N, Anand A, et al. Xpert MTB/XDR performance in non-sputum samples for diagnosis of drug-resistant tuberculosis at a North Indian tertiary care center. Journal of Clinical Microbiology. 2026;64(7). doi:10.1128/jcm.01401-25

BibTeX
@article{Singh2026,
  author = {Singh, Binit Kumar and Jorwal, Pankaj and Thakur, Nishant and Soneja, Manish and Wig, Naveet and Anand, Ankita and Dhawan, Shikha},
  title = {Xpert MTB/XDR performance in non-sputum samples for diagnosis of drug-resistant tuberculosis at a North Indian tertiary care center},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  volume = {64},
  number = {7},
  doi = {10.1128/jcm.01401-25}
}
Kostenlos starten →